BRCA2 and cancer: Here, we designed a 30-gene panel including conventional CRC-predisposing genes and pleiotropic non-CRC-associated cancer susceptibility genes (e.g., BRCA2 and TP53) to explore the germline mutation rate and type in young CRC patients without a family history, and then we compared that information among CRC patients [14,15], polyp patients, and colonoscopy-proven negative individuals.